Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RG7112 |
Synonyms | |
Therapy Description |
RG7112 (RO5045337) binds to the p53-binding region of MDM2 and inhibits MDM2-p53 interaction, resulting in activation of p53 signaling, and decreased tumor cell growth (PMID: 24900694, PMID: 23400593, PMID: 31493899). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RG7112 | RO5045337|RO-5045337 | MDM2 Inhibitor 23 | RG7112 (RO5045337) binds to the p53-binding region of MDM2 and inhibits MDM2-p53 interaction, resulting in activation of p53 signaling, and decreased tumor cell growth (PMID: 24900694, PMID: 23400593, PMID: 31493899). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 mutant | leukemia | decreased response | RG7112 | Phase I | Actionable | In a Phase I clinical trial, the majority of 19 leukemia patients with identified TP53 mutations did not demonstrate response to treatment with RG7112, with 2 acute myeloid leukemia patients harboring TP53 mutations showing clinical activity, but not improvement, and 1 sCLL/CLL patient achieving stable disease (PMID: 26459177). | 26459177 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|